Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1988-5-27
|
pubmed:abstractText |
Twelve patients with congestive heart failure underwent a double-blind, placebo-controlled study for the purpose of examining the central and regional hemodynamic effects of first-dose (1 and 2 mg/kg) oral enoximone, a new phosphodiesterase III inhibitor. Enoximone augmented cardiac output, generally through a positive chronotropic response. Indices of left ventricular contractility, specifically stroke volume, delta P/delta t, fractional shortening rate, and the duration of the preejection period, were only modestly enhanced by enoximone. At 2 mg/kg, systemic vascular resistance fell below baseline values without affecting systemic blood pressure; these parameters were not altered by the 1 mg/kg dose. Both pulmonary artery pressure and pulmonary vascular resistance dropped below baseline and below placebo control for the 2 mg/kg dose. Enoximone at 2 mg/kg lowered right and left heart filling pressures below baseline. Examination of regional hemodynamic responses to both doses demonstrated a reduction in limb vascular resistance and an increase in limb blood flow proportional to the concomitant increase in cardiac output. Renal and hepatic-splanchnic blood flow and vascular resistances were not altered by enoximone. First-dose oral enoximone (1 and 2 mg/kg) alters hemodynamics in heart failure by predominant vasodilatation, particularly of limb-musculoskeletal and pulmonary vascular beds, some positive chronotropism, and modest positive inotropism.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0002-8703
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
115
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1051-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2966546-Adult,
pubmed-meshheading:2966546-Aged,
pubmed-meshheading:2966546-Clinical Trials as Topic,
pubmed-meshheading:2966546-Double-Blind Method,
pubmed-meshheading:2966546-Enoximone,
pubmed-meshheading:2966546-Female,
pubmed-meshheading:2966546-Heart Failure,
pubmed-meshheading:2966546-Hemodynamics,
pubmed-meshheading:2966546-Humans,
pubmed-meshheading:2966546-Imidazoles,
pubmed-meshheading:2966546-Male,
pubmed-meshheading:2966546-Middle Aged,
pubmed-meshheading:2966546-Phosphodiesterase Inhibitors
|
pubmed:year |
1988
|
pubmed:articleTitle |
Central and regional hemodynamic effects of oral enoximone in congestive heart failure: a double-blind, placebo-controlled study.
|
pubmed:affiliation |
Division of Cardiology, College of Medicine, Ohio State University Hospitals, Columbus.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|